Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

MTOR Modulators and Uses Thereof

a technology of mtor and modulator, which is applied in the direction of chemical treatment enzyme inactivation, drug composition, cardiovascular disorder, etc., can solve problems such as apoptosis or cell cycle arrest, and achieve the effect of enhancing the effect of said treatmen

Inactive Publication Date: 2011-09-15
RGT UNIV OF CALIFORNIA
View PDF101 Cites 103 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes methods for selectively inhibiting the activity of mTorC1 and mTorC2, which are proteins involved in cell proliferation and cancer development. The methods involve using biologically active agents that selectively inhibit the activity of these proteins relative to other proteins in the body. The methods can be used to treat cancer and other medical conditions associated with mTorC1 and mTorC2 activity. The biologically active agents can be administered to patients in need of treatment. The patent also describes a method of inhibiting cell proliferation by using an antagonist that inhibits full activation of Akt, a protein involved in cell proliferation, in combination with an anti-cancer agent. Overall, the patent provides new tools for developing effective treatments for cancer and other medical conditions associated with mTorC1 and mTorC2 activity.

Problems solved by technology

The inhibition methods can cause apoptosis or cell cycle arrest.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • MTOR Modulators and Uses Thereof
  • MTOR Modulators and Uses Thereof
  • MTOR Modulators and Uses Thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Kinase Inhibition Assay

[0228]Purified kinase domains (e.g. mTor, P110α, P110β, P110γ, P110δ, PI4Kβ, DNA-PK, PKCα, PKCβ1, PKCβII, RET, and JAK2) were incubated with inhibitors at 2- or 4-fold dilutions over a concentration range of 50-0.001 μM or with vehicle (0.1% DMSO) in the presence of 10 μM ATP, 2.5 μCi of γ-32P-ATP and substrate. Reactions were terminated by spotting onto nitrocellulose or phosphocellulose membranes, depending on the substrate; this membrane was then washed 5-6 times to remove unbound radioactivity and dried. Transferred radioactivity was quantitated by phosphorimaging and IC50 values were calculated by fitting the data to a sigmoidal dose-response using Prism software.

[0229]The results as shown in FIG. 2 demonstrate that TORKinib is a potent and specific inhibitor of mTor with an IC50 of about 8 nM. TORKinib was also relatively inactive against PKCβ, RET, and JAK2 (V617F), but inhibited PKCα with an IC50 of about 50 nM. TORKinib2 likewise is an extremely poten...

example 2

Effect of mTor Inhibitors on Kinase Substrate Phosphorylation

[0230]L6 myoblasts were grown typically grown in DMEM supplemented with about 10% FBS, glutamine and penicillin / streptomycin. Confluent L6 myoblasts were differentiated into myotubes by culturing them for approximately 5 days in media containing about 2% FBS. L6 myotubes were maintained in media containing approximately 2% FBS until use.

[0231]In order to compare the effect of TORKinibs and PIK-90 on Akt phosphorylation, L6 myotubes were serum starved overnight and incubated with inhibitors or about 0.1% DMSO for approximately 30 minutes prior to stimulation with insulin (e.g. 100 nM) for about 10 minutes. Cells were lysed by scraping into ice cold lysis buffer (generally: 300 mM NaCl, 50 mM Tris pH 7.5, 5 mM EDTA, 1% Triton X-100, 0.02% NaN3, 20 nM microcystin, Sigma phosphatase inhibitor cocktails 1 and 2, Roche protease inhibitor cocktail and 2 mM PMSF). After contacting cells with lysis buffer, the solution was briefly ...

example 3

Kinetics of Kinase Substrate Phosphorylation

[0233]L6 myotubes were serum starved overnight and incubated with TORKinib or 0.1% DMSO for about 30 minutes prior to stimulation with insulin (e.g. 100 nM) for about 1, 3, 10, and 60 minutes. Cells were lysed by scraping into ice cold lysis buffer (generally 300 mM NaCl, 50 mM Tris pH 7.5, 5 mM EDTA, 1% Triton X-100, 0.02% NaN3, 20 nM microcystin, Sigma phosphatase inhibitor cocktails 1 and 2, Roche protease inhibitor cocktail and 2 mM PMSF). After contacting cells with lysis buffer, the solution was briefly sonicated. Lysates were cleared by centrifugation, resolved by SDS-PAGE, transferred to nitrocellulose and immunoblotted using antibodies to phospho-Akt S473, phospho-Akt T308, and actin. The results as shown in FIG. 4 demonstrate that differential sensitivity of S473 and T308 to inhibition of phosphorylation by TORKinibs may not reflect differing kinetics of phosphorylation.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides methods and compositions for selective modulation of certain protein kinases, and especially mTor complexes. The methods and compositions are particularly useful in inhibiting mTor selectively for therapeutic applications.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application No. 61 / 079,103, filed Jul. 8, 2008, which is hereby incorporated by reference in its entirety and for all purposes.STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT[0002]This invention was made at least in part with government support under R01-DK56695, AI44009, and DK007636 awarded by the National Institutes of Health. The Government has certain rights in the invention.BACKGROUND OF THE INVENTION[0003]Abnormal cellular proliferation, a hallmark of cancer, can result from a wide range of cellular phenomena. Proliferative signals are transmitted into and within a cell via a process known as signal transduction. Over the past decades, cascades of signal transduction pathways have been elucidated and found to play a central role in a variety of biological responses. Defects in various components of signal transduction pathways have ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/506C12N5/09C12N9/99A61K31/519A61K31/436A61P35/00A61P13/12A61P9/12A61P9/04A61P1/16
CPCC12Q1/485G01N2510/00G01N2500/04A61K31/519A61P1/16A61P9/04A61P9/12A61P13/12A61P35/00
Inventor SHOKAT, KEVAN M.FRUMAN, DAVIDREN, PINGDAWILSON, TROY EDWARDLI, LIANSHENGHSIEH, ANDREWFELDMAN, MORRISAPSEL, BETHLIU, YIROMMEL, CHRISTIANCHAN, KATRINARUGGERO, DAVIDEPEARCE, DAVIDJANES, MATTHEW
Owner RGT UNIV OF CALIFORNIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com